{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:26:30Z","timestamp":1707524790016},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"DOI":"10.7759\/cureus.33384","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:50:30Z","timestamp":1672919430000},"source":"Crossref","is-referenced-by-count":0,"title":["Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism"],"prefix":"10.7759","author":[{"given":"Sifan","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria D","family":"McDow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeb","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tieying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198901000-00011","article-title":"C-cell hyperplasia of the thyroid in a patient with goitrous hypothyroidism and Hashimoto's thyroiditis","volume":"13","author":"Libbey NP","year":"1989","unstructured":"Libbey NP, Nowakowski KJ, Tucci JR. C-cell hyperplasia of the thyroid in a patient with goitrous hypothyroidism and Hashimoto's thyroiditis. Am J Surg Pathol. 1989, 13:71-7. 10.1097\/00000478-198901000-00011","journal-title":"Am J Surg Pathol"},{"key":"ref2","article-title":"Sporadic C-cell hyperplasia associated with multinodular goiter (Article in Italian)","volume":"98","author":"Volante M","year":"2006","unstructured":"Volante M. Sporadic C-cell hyperplasia associated with multinodular goiter (Article in Italian). Pathologica. 2006, 98:160-3.","journal-title":"Pathologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(88)80262-4","article-title":"C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors","volume":"19","author":"Albores-Saavedra J","year":"1988","unstructured":"Albores-Saavedra J, Monforte H, Nadji M, Morales AR. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol. 1988, 19:795-9. 10.1016\/s0046-8177(88)80262-4","journal-title":"Hum Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1992.tb00433.x","article-title":"C-cell hyperplasia in secondary hyperparathyroidism","volume":"21","author":"Tomita T","year":"1992","unstructured":"Tomita T, Millard DM. C-cell hyperplasia in secondary hyperparathyroidism. Histopathology. 1992, 21:469-74. 10.1111\/j.1365-2559.1992.tb00433.x","journal-title":"Histopathology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7739","article-title":"634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia","volume":"86","author":"Diaz-Cano SJ","year":"2001","unstructured":"Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Wolfe HJ. Germline RET: 634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. J Clin Endocrinol Metab. 2001, 86:3948-57. 10.1210\/jcem.86.8.7739","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd RA","year":"2015","unstructured":"Byrd RA, Sorden SD, Ryan T, et al.. Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents. Endocrinology. 2015, 156:2417-28. 10.1210\/en.2014-1722","journal-title":"Endocrinology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2318","article-title":"GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide","volume":"96","author":"Heged\u00fcs L","year":"2011","unstructured":"Heged\u00fcs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011, 96:853-60. 10.1210\/jc.2010-2318","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali G","year":"2021","unstructured":"Mali G, Ahuja V, Dubey K. Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2021, 46:99-105. 10.1111\/jcpt.13259","journal-title":"J Clin Pharm Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed YY","year":"2022","unstructured":"Syed YY. Tirzepatide: first approval. Drugs. 2022, 82:1213-20. 10.1007\/s40265-022-01746-8","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19960215)77:4750::aid-cncr223.0.co;2-z","article-title":"Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities","volume":"77","author":"Perry A","year":"1996","unstructured":"Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer. 1996, 77:4-750. 10.1002\/(sici)1097-0142(19960215)77:4750::aid-cncr223.0.co;2-z","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s002920100468","article-title":"\"Physiological\" and \"neoplastic C-cell hyperplasia of the thyroid. Morphologically and biologically distinct entities? (Article in German)","volume":"22","author":"Hinze R","year":"2001","unstructured":"Hinze R, Gimm O, Brauckhoff M, Schneyer U, Dralle H, Holzhausen HJ. \"Physiological\" and \"neoplastic C-cell hyperplasia of the thyroid. Morphologically and biologically distinct entities? (Article in German). Pathologe. 2001, 22:259-65. 10.1007\/s002920100468","journal-title":"Pathologe"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-06-0053","article-title":"Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?","volume":"14","author":"Verga U","year":"2007","unstructured":"Verga U, Ferrero S, Vicentini L, et al.. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?. Endocr Relat Cancer. 2007, 14:393-403. 10.1677\/ERC-06-0053","journal-title":"Endocr Relat Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(95)90294-5","article-title":"Immunostains for collagen type IV discriminate between C-cell hyperplasia and microscopic medullary carcinoma in multiple endocrine neoplasia, type 2a","volume":"26","author":"McDermott MB","year":"1995","unstructured":"McDermott MB, Swanson PE, Wick MR. Immunostains for collagen type IV discriminate between C-cell hyperplasia and microscopic medullary carcinoma in multiple endocrine neoplasia, type 2a. Hum Pathol. 1995, 26:1308-12. 10.1016\/0046-8177(95)90294-5","journal-title":"Hum Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030550","article-title":"Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders","volume":"89","author":"Elisei R","year":"2004","unstructured":"Elisei R, Bottici V, Luchetti F, et al.. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004, 89:163-8. 10.1210\/jc.2003-030550","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen L","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, Andersen S, et al.. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010, 151:1473-86. 10.1210\/en.2009-1272","journal-title":"Endocrinology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier B","year":"2012","unstructured":"Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012, 97:121-31. 10.1210\/jc.2011-2407","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2028","article-title":"Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL)","volume":"42","author":"Bethel MA","year":"2019","unstructured":"Bethel MA, Patel RA, Thompson VP, et al.. Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL). Diabetes Care. 2019, 42:1075-80. 10.2337\/dc18-2028","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao C","year":"2019","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019, 66:157-65. 10.1007\/s12020-019-02055-z","journal-title":"Endocrine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff M","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011, 141:150-6. 10.1053\/j.gastro.2011.02.018","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases","volume":"47","author":"Wang J","year":"2022","unstructured":"Wang J, Kim CH. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022, 47:18-25. 10.1080\/07435800.2021.1955255","journal-title":"Endocr Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131904-multifocal-c-cell-hyperplasia-and-marked-hypercalcitoninemia-in-a-diabetic-patient-treated-with-glucagon-like-peptide-1-agonist-with-concurrent-multinodular-goiter-and-hyperparathyroidism","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:32Z","timestamp":1707508052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131904-multifocal-c-cell-hyperplasia-and-marked-hypercalcitoninemia-in-a-diabetic-patient-treated-with-glucagon-like-peptide-1-agonist-with-concurrent-multinodular-goiter-and-hyperparathyroidism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.33384","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}